LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan Bradbury, Equillium’s chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019.
|Date:||Monday, April 8, 2019|
|Time:||12:10 PM BST | 4:10 AM Pacific Time|
|Location:||JW Marriott Grosvenor House, London, UK|
A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the activity and trafficking of Teff cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to EQ001 through an exclusive partnership with Biocon Limited. Equillium believes that EQ001 has the potential to be a best-in-class disease modifying therapeutic and is advancing EQ001 into clinical development in multiple immuno-inflammatory indications with high unmet medical need. For more information, visit www.equilliumbio.com.
Heidi Chokeir, Ph.D.